Zheng Zhang,Peng Tan,Baoguo Mi,Chao Song,Yi Deng,Hanfeng Guan. Therapy for bone metastasis from different cancers. Oncol Transl Med, 2016, 2: 55-60.
Therapy for bone metastasis from different cancers
Received:February 01, 2016  Revised:March 18, 2016
View Full Text  View/Add Comment  Download reader
KeyWord:bone metastasis; skeletal-related events (SREs); therapy
Author NameAffiliationE-mail
Zheng Zhang Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology zhenren_122@163.com 
Peng Tan Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology zhenren_122@163.com 
Baoguo Mi Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology zhenren_122@163.com 
Chao Song Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology zhenren_122@163.com 
Yi Deng Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology zhenren_122@163.com 
Hanfeng Guan Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology hguan@hust.edu 
Hits: 6032
Download times: 7138
Abstract:
      The bone is the most common target organ of cancer metastasis. Bone metastasis leads to considerable morbidity due to skeletal-related events (SREs). These include bone pain, hypercalcemia, pathologic fractures, and compression of the spinal cord. Cancers such as those of the lung, breast, prostate, and kidney are more likely to cause SREs than other cancer types. Additionally, some blood cancers, including multiple myeloma and lymphoma, frequently cause SREs. In this article, we review the conventional therapies for metastatic bone disease, including drug therapy, radiotherapy, and surgery. Among osteoclast-targeting agents, bisphosphonates and nuclear factor kappa-B ligand inhibitors are the most widely used agents to prevent cancer-related bone loss. Unsealed radioisotopes are also considered promising in cancer therapy. Currently, iodine-131, strontium-89, and radium-223 are available for the treatment of bone metastasis. However, the treatments for blood cancers with SREs are different from those of other cancers. In those cases, new classes of agents including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and histone deacetylase inhibitors have shown remarkable efficacy. We also discuss the potential development of new therapies for these diseases.
Close